A roadmap for drug discovery and its translation to small molecule agents in clinical development for tuberculosis treatment

Tuberculosis

Volumn 88, Issue SUPPL. 1, 2008, Pages

  Showalter, H D Hollis ^a   Denny, William A ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Diarylquinolines; Drug discovery; Fluoroquinolones; Mycobacterium; Nitroimidazooxazines; Nitroimidazooxazoles; Oxazolidinones; Tuberculosis; tuberculosis

Indexed keywords

1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMIKACIN; CGI 17341; CYTOCHROME P450; DA 7157; DA 7218; DA 7867; DOFETILIDE; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; KRQ 10018; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; OPC 67683; OXAZINE DERIVATIVE; OXAZOLE DERIVATIVE; OXAZOLIDINONE DERIVATIVE; PNU 100480; PYRAZINAMIDE; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE; RANBAXY; RANBEZOLID; RIFAMPICIN; RIFAPENTINE; SITAFLOXACIN; SPARFLOXACIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AREA UNDER THE CURVE; ARTICLE; ASSAY; BACTERIAL CELL WALL; CLINICAL TRIAL; DRUG ABSORPTION; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG DISCOVERY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; FUNCTIONAL GENOMICS; GENE; GENE FUNCTION; GENOMICS; GLUCOSE BLOOD LEVEL; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN GENOME; KNOCKOUT GENE; LEAD OPTIMIZATION; MICRONUCLEUS TEST; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NONLINEAR SYSTEM; PRIORITY JOURNAL; PROTEOMICS; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; TUBERCULOSIS; VALIDATION PROCESS;

ANIMALS; ANTITUBERCULAR AGENTS; DRUG DESIGN; DRUG EVALUATION; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; DRUGS, INVESTIGATIONAL; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 50449096102     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-9792(08)70032-5     Document Type: Article

References (121)

1. For information on the IND and NDA filing process. see: http://www.fda.gov/CDER/regulatory/applications/
2. DiMasi J.A., Hansen R.W., and Grabowski H.G. The price of innovation: new estimates of drug development costs?. J Health Econ 22 (2003) 151-185
3. Pariza R.J. From patent to prescription: paving the perilous path to profit. In: Chorghade M.S. (Ed). Drug discovery and development volume 1 (2006), Wiley, Hoboken NJ 1-16
4. Overington J.P., Al-Lazikani B., and Hopkins A.L. How many drug targets are there?. Nat Rev Drug Discov 5 (2006) 993-996
5. Al-Lazikani B., Gaulton A., Paolini G., Lanfear J., Overington J., and Hopkins A. The molecular basis of predicting druggability. In: Schreiber S.L., Kapoor T.M., and Wess G. (Eds). Chemical biology? From small molecules to system biology and drug design volume 3 (2007), Wiley-VCH Verlag, Weinheim Germany 804-823
6. Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G., et al. The sequence of the human genome?. Science 291 (2001) 1304-1351
7. Banks R.E., Dunn M.J., Hochstrasser D.F., Sanchez J.-C., Blackstock W., Pappin D.J., and Selby P.J. Proteomics: new perspectives, new biomedical opportunities. Lancet 356 (2000) 1749-1756
8. Stark G.R., and Gudkov A.V. Forward genetics in mammalian cells: functional approaches to gene discovery?. Hum Mol Genet 8 (1999) 1925-1938
9. Lipinski C., and Hopkins A. Navigating chemical space for biology and medicine?. Nature 432 (2004) 855-861
10. Luttrell L.M. Transmembrane signaling by G proteincoupled receptors?. Methods Mol Biol 332 (2006) 3-49
11. Johnson S.A., and Hunter T. Kinomics: methods for deciphering the kinome?. Nat Methods 2 (2005) 17-25
12. Moos W.H. The intersection of strategy and drug research. In: Taylor J.B., and Triggle D.J. (Eds). Comprehensive medicinal chemistry II volume 2 (2006), Elsevier, Oxford 1-84
13. Tenson T., and Mankin A. Antibiotics and the ribosome?. Mol Microbiol 59 (2006) 1664-1677
14. Ma Z., Ginsberg A.M., and Spigelman M. Antimycobacterium agents. In: Taylor J.B., and Triggle D.J. (Eds). Comprehensive medicinal chemistry II volume 7 (2006), Elsevier, Oxford 699-730
15. Liu J., and Ren H.P. Tuberculosis: current treatment and new drug development?. Anti Infect Agents Med Chem 5 (2006) 331-344
16. Cole S.T., Brosch R., Parkhill J., Garnier T., Churcher C., Harris D., et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence?. Nature 393 (1998) 537-544
17. Camus J.C., Pryor M.J., Médigue C., and Cole S.T. Re-annotation of the genome sequence of Mycobacterium tuberculosis H37Rv?. Microbiology 148 (2002) 2967-2973
18. Sassetti C.M., Boyd D.H., and Rubin E.J. Genes required for mycobacterial growth defined by high density mutagenesis?. Mol Microbiol 48 (2003) 77-84
19. Tsolaki A.G., Hirsh A.E., DeRiemer K., Enciso J.A., Wong M.Z., Hannan M., Goguet dla Salmoniere Y., Aman K., KatoMaeda M., and Small P.M. Functional and evolutionary genomics of Mycobacterium tuberculosis: insights from genomic deletions in 100 strains?. Proc Natl Acad Sci USA 101 (2004) 4865-4870
20. Balganesh T.S., and Furr B. Molecular approaches to target discovery: evaluating targets for antituberculosis drug discovery programmes?. Inf Dis Drug Targets 7 (2007) 120-126
21. Barry C.E., Crick D.C., and McNeil M.R. Targeting the formation of the cell wall core of M. tuberculosis?. Inf Dis Drug Targets 7 (2007) 182-202
22. Murillo A.C., Li H.Y., Alber T., Baker E.N., Berger J.M., Cherney L.T., et al. High throughput crystallography of TB drug targets?. Inf Dis Drug Targets 7 (2007) 127-139
23. Harris S., and Foord S.M. Transgenic gene knock-outs: functional genomics and therapeutic target selection?. Pharmacogenomics 1 (2000) 433-443
24. Sakaguchi S., and Sakaguchi N. Animal models of arthritis caused by systemic alteration of the immune system?. Curr Opin Immunol 17 (2005) 589-594
25. Natt F. siRNAs in drug discovery: target validation and beyond?. Curr Opin Mol Ther 9 (2007) 242-247
26. Houdebine L.-M. Transgenic animal models in biomedical research?. Methods Mol Biol 360 (2007) 163-202
27. Darvas F., Dorman G., Puskas L.G., Bucsai A., and Urge L. Chemical genomics for fast and integrated target identification and lead optimization?. Med Chem Res 13 (2004) 643-659
28. Butcher E.C. Innovation: can cell systems biology rescue drug discovery?. Nat Rev Drug Discov 4 (2005) 461-467
29. Kunapuli P., Zheng W., Weber M., Solly K., Mull R., Platchek M., Cong M., Zhong Z., and Strulovici B. Application of division arrest technology to cell-based HTS: comparison with frozen and fresh cells?. Assay Drug Dev Technol 3 (2005) 17-26
30. Scheer A. Future trends in screening technology for drug discovery?. Expert Opin Drug Discov 1 (2006) 195-198
31. Rishton G.M. Reactive compounds and in vitro fake positives in HTS?. Drug Discov Today 2 (1997) 382-384
32. Rishton G.M. Nonleadlikeness and leadlikeness in biochemical screening?. Drug Discov Today 8 (2003) 86-96
33. Davis A.M., Keeling D.J., Steele J., Tomkinson N.P., and Tinker A.C. Components of successful lead generation?. Curr Top Med Chem 5 (2005) 421-439
34. Banks M.N., Zhang L., and Houston J.G. Screen/counter-screen: early assessment of selectivity. In: Bartlett P.A., and Entzeroth M. (Eds). Exploiting chemical diversity for drug discovery (2006), Royal Society of Chemistry, Cambridge UK 315-335
35. Shelat A.A., and Guy R.K. The interdependence between screening methods and screening library?. Curr Opin Chem Biol 11 (2007) 244-251
36. YP P. In silico drug discovery: solving the "target-rich and lead-poor" imbalance using the genome-to-drug-lead paradigm?. Clin Pharm Ther 81 (2007) 30-34
37. Geldenhuys W.J., Gaasch K.E., Watson M., Allen D.D., and Van de Schyf C.J. Optimizing the use of open-source software applications in drug discovery?. Drug Discov Today 11 (2006) 127-132
38. Pozzan A. Molecular descriptors and methods for ligand based virtual high throughput screening in drug discovery?. Curr Pharm Des 12 (2006) 2099-2110
39. Payne D.J., Gwynn M.N., Holmes D.J., and Pompliano D.L. Drugs for bad bugs: confronting the challenges of antibacterial discovery?. Nat Rev Drug Disc 6 (2007) 29-40
40. Bhat J., Rane R., Solapure S.M., Sarkar D., Sharma U., Harish M.N., et al. High-throughput screening of RNA polymerase inhibitors using a fluorescent UTP analog?. J Biomol Screen 11 (2006) 968-976
41. He X., Alian A., Stroud R., and Ortiz d Montellano P.R. Pyrrolidine carboxamides as a novel class of inhibitors of enoyl acyl carrier protein reductase from Mycobacterium tuberculosis?. J Med Chem 49 (2006) 6308-6323
42. Singh U., and Sarkar D. Development of a simple highthroughput screening protocol based on biosynthetic activity of Mycobacterium tuberculosis glutamine synthetase for the identification of novel inhibitors?. J Biomol Screen 11 (2006) 1035-1042
43. White E.L., Southworth K., Ross L., Cooley S., Gill R.B., Sosa M.I., et al. A novel inhibitor of Mycobacterium tuberculosis panthothenate synthetase?. J Biomol Screen 12 (2007) 100-105
44. Agrawal H., Kumar A., Bal N.C., Siddiqi M.I., and Arora A. Ligand based virtual screening and biological evaluation of inhibitors of chorismate mutase (Rv1885c) from Mycobacterium tuberculosis H37Rv?. Bioorg Med Chem Lett 17 (2007) 3053-3058
45. Cho S.H., Warit S., Wan B., Hwang C.H., Pauli G.F., and Franzblau S.G. Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis?. Antimicrob Agents Chemother 51 (2007) 1380-1385
46. Raghunand T.R., Bishai W.R., and Chen P. Towards establishing a method to screen for inhibitors of essential genes in mycobacteria: evaluation of the acetamidase promoter?. Int J Antimicrob Agents 28 (2006) 36-41
47. Goldman R.C., Laughon B.E., Reynolds R.C., Secrist III J., Maddry J.A., Guie M.-A., et al. Programs to facilitate tuberculosis drug discovery: the Tuberculosis Antimicrobial Acquisition and Coordinating Facility?. Inf Dis Drug Targets 7 (2007) 92-104
48. Edwards P.J., Allart B., Andrews M., Clase J.A., and Menet C. Expediting drug discovery: recent advances in fast medicinal chemistry-optimization of hits and leads?. Curr Opin Drug Discov Devel 9 (2006) 425-444
49. Cirovic D.A., Bhargava V., Harrison F., Vaz R., and Laoui A. In silico methods and predictive tools along the drug discovery value chain?. Pharm Discov 5 (2005) 30-35
50. Scapin G. Structural biology and drug discovery?. Curr Pharm Des 12 (2006) 2087-2097
51. Finlayson K., and Sharkey J. A high-throughput binding assay for HERG. In: Yan Z., and Caldwell G.W. (Eds). Optimization in drug discovery: in vitro methods (2004), Humana, Totowa NJ 353-368
52. Xu J.J. In vitro toxicology: bringing the in silico and in vivo. In: Ekins S. (Ed). Computational toxicology: risk assessment for pharmaceutical and environmental chemicals (2007), Wiley, Hoboken NJ 21-32
53. Hsieh Y., and Korfmacher W.A. Increasing speed and throughput when using HPLC-MS/MS systems for drug metabolism and pharmacokinetic screening?. Curr Drug Metab 7 (2006) 479-489
54. Evans D.C., Watt A.P., Nicoll-Griffith D.A., and Baillie T.A. Drugprotein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem Res Toxicol 17 (2004) 3-16
55. Keller T.H., Pichota A., and Yin Z. A practical view of druggability?. Curr Opin Chem Biol 10 (2006) 457-461
56. Silva C.H.T.P., Leopoldino A.M., and Taft C.A. General aspects of lead finding and optimization in drug discovery?. Curr Methods Med Chem Biol Phys 1 (2007) 33-48
57. Kuhlmann J., and Wensing G. The applications of biomarkers in early clinical drug development to improve decisionmaking processes?. Curr Clin Pharmacol 1 (2006) 185-191
58. Balani S.K., Miwa G.T., Gan L.-S., Wu J.-T., and Lee F.W. Strategy of utilizing in vitro and in vivo ADME tools for lead optimization and drug candidate selection?. Curr Top Med Chem 5 (2005) 1033-1038
59. DeWitte, Robert S., Robins, and Russell H. A hierarchical screening methodology for physicochemical/ADME /tox profiling?. Expert Opin Drug Metab Toxicol 2 (2006) 805-817
60. Parry J.M., and Parry E.M. The use of the in vitro micronucleus assay to detect and assess the aneugenic activity of chemicals?. Mutat Res Genet Toxicol Environ Mutagen 607 (2006) 5-8
61. Brown A.M. hERG assay, QT liability, and sudden cardiac death. In: Morganroth J., and Gussak I. (Eds). Cardiac safety of noncardiac drugs: practical guidelines for clinical research and drug development (2005), Humana, Totowa NJ 67-81
62. Vormberge T., Hoffmann M., and Himmel H. Safety pharmacology assessment of drug-induced QT-prolongation in dogs with reduced repolarization reserve?. J Pharmacol Toxicol Methods 54 (2006) 130-140
63. Vangala S., and Tonelli A. Biomarkers, metabonomics, and drug development:can inborn errors of metabolism help in understanding drug toxicity?. AAPS J 9 (2007) E284-E297
64. Froloff N., Hamon V., Dupuis P., Otto-Bruc A., Mao B., Merrick S., and Migeon J. Construction of a homogeneous and informative in vitro profiling database for anticipating the clinical effects of drugs. In: Jacoby E. (Ed). Chemogenomics: knowledge-based approaches to drug discovery (2006), Imperial College Press, London 175-206
65. Stevens J.L. Future of toxicologymechanisms of toxicity and drug safety: where do we go from here?. Chem Res Toxicol 19 (2006) 1393-1401
66. Hariharan M., Ganorkar L.D., Amidon G.E., Cavallo A., Gatti P., Hageman M.J., et al. Reducing the time to develop and manufacture formulations for first oral dose in humans?. Pharm Technol 27 (2003) 68-84
67. O'Connor K.A., and Roth B.L. Finding new tricks for old drugs: an efficient route for public-sector drug discovery?. Nat Rev Drug Discov 4 (2005) 1005-1014
68. Chong C.R., and Sullivan Jr. D.J. New uses for old drugs?. Nature 448 (2007) 645-646
69. In: Smith C.G., and O'Donnell J. (Eds). The process of new drug discovery and development (2006), Taylor & Francis, Boca Raton
70. Laurenzi M., Ginsberg A., and Spigelman M. Challenges associated with current and future TB treatment?. Inf Dis Drug Targets 7 (2007) 105-119
71. Tsukamura M. In vitro antituberculosis activity of a new antibacterial substance, ofloxacin (DL8280)?. Am Review Resp Dis 131 (1985) 348-351
72. Tsukamura M., Nakamura E., Yoshii S., and Amano H. Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis?. Am Rev Respir Dis 131 (1985) 352-356
73. Crofton J., Chouculet P., and Maher D. Guidelines for the management of drug-resistant tuberculosis WHO/TB/96-210 (rev.1) (1997), World Health Organization, Geneva
74. Centers for Disease Control and Prevention. Treatment of Tuberculosis, American Thoracic Society, CDC, and Infectious Diseases Society of America. Treatment of Tuberculosis?. Morbidity and Mortality Weekly Report 52 RR11 (2003) 1
75. Mdluli K., and Ma Z. Mycobacterium tuberculosis DNA gyrase as a target for drug discovery?. Inf Dis Drug Targets 7 (2007) 159-168
76. De Souza M.V.N., Vasconcelos T., de Almeida M.V., and Cardoso S.H. Fluoroquinolones: an important class of antibiotics against tuberculosis?. Curr Med Chem 13 (2006) 455-463
77. Gellert M., Mizuuchi K., O'Dea M.H., Itoh T., and Tomizawa J.L. DNA gyrase: An enzyme that introduces superhelical turns into DNA?. Proc Natl Acad Sci USA 73 (1976) 3872-3876
78. Shen L.L., and Pernet A.G. Mechanism of inhibition of DNA gyrase by analogs of nalidixic acid: the target of the drugs is DNA. Proc Natl Acad Sci USA 82 (1985) 307-311
79. Shen L.L., Mitscher L.A., Sharma P.N., O'Donnell T.J., Chu D.W., Cooper C.S., Rosen T., and Pernet A.G. Mechanism of inhibition of DNA gyrase by quinolone antibacterials: a cooperative drug-DNA binding model?. Biochemistry 28 (1989) 3886-3894
80. Champoux J.J. DNA topoisomerases: structure, function, and mechanism?. Annu Rev Biochem 70 (2001) 369-413
81. Sekiguchi J.-I., Miyoshi-Akiyama T., Augustynowicz-Kopec E., Zwolska Z., Kirikae F., Toyota E., Kobayashi I., Morita K., Kudo K., Kato S., Kuratsuji T., Mori T., and Kirikae T. Detection of multidrug resistance in Mycobacterium tuberculosis?. J Clin Microbiol 45 (2007) 179-192
82. Wang J.-Y., Lee L.-N., Lai H.-C., Wang S.-K., Jan I.-S., Yu C.-J., Hsueh P.-R., and Yang P.-C. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure. J?. Antimicrob Chemother 59 (2007) 860-865
83. Yew W.W., Kwan S., Ma W.K., Aung M.K., and Chau P.Y. In vitro activity of ofloxacin against Mycobacterium tuberculosis and its clinical efficacy in multiply resistant pulmonary tuberculosis?. J Antimicrob Chemother 26 (1990) 227-236
84. Alvarez-Freites E.J., Carter J.L., and Cynamon M.H. In Vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 46 (2002) 1022-1025
85. Gillespie S.H., and Billington O. Activity of moxifloxacin against mycobacteria?. J Antimicrob Chemother 44 (1999) 393-395
86. Bhusal Y., Shiohira C.M., and Yamane N. Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis?. Int J Antimicrob Agents 26 (2005) 292-297
87. Onodera Y., Tanaka M., and Sato K. Inhibitory activity of quinolones against DNA gyrase of Mycobacterium tuberculosis?. J Antimicrob Chemother 44 (2001) 447-450
88. Johnson J.L., Hadad D.J., Boom W.H., Daley C.L., Peloquin C.A., Eisenach K.D., Jankus D.D., Debanne S.M., Charlebois E.D., Maciel E., Palaci M., and Dietze R. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis?. Int J Tuberc Lung Dis 10 (2006) 605-612
89. Cynamon M., Sklaney M.R., and Shoen C. Gatifloxacin in combination with rifampicin in a murine tuberculosis model?. J Antimicrob Chemother 60 (2007) 429-432
90. Davies P., and Yew W.W. Recent developments in the treatment of tuberculosis?. Expert Opin Invest Drugs 12 (2003) 1297-1321
91. Shandil R.K., Jayaram R., Kaur P., Gaonkar S., Suresh B.L., Mahesh B.N., Jayashree R., Nandi V., Bharath S., and Balasubramanian V. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy?. Antimicrob Agents Chemother 51 (2007) 576-582
92. Sato K., Tomioka H., Sano C., Shimizu T., Sano K., Ogasawara K., Cai S., and Kamei T. Comparative antimicrobial activities of gatifloxacin, sitafloxacin and levofloxacin against Mycobacterium tuberculosis replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines?. J Antimicrob Chemother 52 (2003) 199-203
93. Sood R., Bhadauriya T., Rao M., Gautam R., Malhotra S., Barman T.K., Upadhyay D.J., and Rattan A. Antimycobacterial activities of oxazolidinones: a review?. Infect Dis Drug Targets 6 (2006) 343-354
94. Shinabarger D.L., Marotti K.R., Murray R.W., Lin A.H., Melchior E.P., Swaney S.M., Dunyak D.S., Demyan W.F., and Buysse J.M. Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions?. Antimicrob Agents Chemother 41 (1997) 2132-2136
95. Alcalà L., Ruiz-Serrano M.J., Pèrez-Fernàndez Turégano C., de Viedma D.G., Diàz-Infantes M., Marìn-Arriaza M., and Bouza E. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs?. Antimicrob Agents Chemother 47 (2003) 416-417
96. Barbachyn M.R., Hutchinson D.K., Brickner S.J., Cynamon M.H., Kilburn J.O., Klemens S.P., Glickman S.E., Grega K.C., Hendges S.K., Toops D.S., Ford C.W., and Zurenko G.E. Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity?. J Med Chem 39 (1996) 680-685
97. Cynamon M.H., Klemens S.P., Sharpe C.A., and Chase S. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model?. Antimicrob Agents Chemother 43 (1999) 1189-1191
98. Das B., Rudra S., Yadav A., Ray A., Rao A., Srinivas A., Soni A., Saini S., Shukla S., Pandya M., Bhateja P., Malhotra S., Mathur T., Arora S.K., Rattan A., and Mehta A. Synthesis and SAR of novel oxazolidinones: discovery of ranbezolid?. Bioorg Med Chem Lett 15 (2005) 4261-4267
99. Biava M., Porretta G.C., Deidda D., and Pompei R. New trends in development of antimycobacterial compounds?. Infect Dis Drug Targets 6 (2006) 159-172
100. Artico M., Mai A., Sbardella G., Massa S., Lampis G., Deidda D., and Pompei R. N-[4-(1,1'-Biphenyl)methyl]-4-(4-thiomorpho-linylmethyl)benzenamines as non-oxazolidinone analogs of antimycobacterial U-100480?. Bioorg Med Chem Lett 8 (1998) 1493-1498
101. Vera-Cabrera L., Gonzalez E., Rendon A., Ocampo-Candiani J., Welsh O., Velazquez-Moreno V.M., Choi S.H., and Molina-Torres C. 2006. In vitro activities of DA-7157 and DA-7218 against Mycobacterium tuberculosis and Nocardia brasiliensis?. Antimicrob Agents Chemother 50 (2006) 3170-3172
102. Bae S.K., Yang S.H., Shin K.N., Rhee J.K., Yoo M., and Lee M.G. Pharmacokinetics of DA-7218, a new oxazolidinone, and its active metabolite, DA-7157, after intravenous and oral administration of DA-7218 and DA-7157 to rats?. J Pharm Pharmacol 59 (2007) 955-963
103. Andries K., Verhasselt P., Guillemont J., Goehlmann H.W.H., Neefs J.-M., Winkler H., Van Gestel J., Timmerman P., Zhu M., Lee E., Williams P., de Chaffoy D., Huitric E., Hoffner S., Cambau E., Truffot-Pernot C., Lounis N., Jarlier V., and A d. drug active on the ATP synthase of Mycobacterium tuberculosis?. Science 307 (2005) 223-227
104. Koul A., Dendouga N., Vergauwen K., Molenberghs B., Vranckx L., Willebrords R., Ristic Z., Lill H., Dorange I., Guillemont J., Bald D., and Andries K. Diarylquinolines target subunit c of mycobacterial ATP synthase?. Nature Chem Biol 3 (2007) 323-324
105. Petrella S., Cambau E., Chauffour A., Andries K., Jarlier V., and Sougakoff W. Genetic basis for natural and acquired resistance to the diarylquinoline R207910 in mycobacteria?. Antimicrob Agents Chemother 50 (2006) 2853-2856
106. Porstmann FR, Horns S, Bader T. Process for preparing ([.alpha]S, [.beta]R)-6-bromo-[.alpha]-[2-(dimethylamino)ethyl]-2-methoxy-[.alpha]-( 1-naphthalenyl)-[.beta]-phenyl-3-quinolineethanol (Janssen Pharmaceutica N.V.). WO 2006125769 A1, 34 pp, published 30 Nov 2006.
107. Lounis N., Veziris N., Chauffour A., Truffot-Pernot C., Andries K., and Jarlier V. Combinations of R207910 with drugs used to treat tuberculosis have the potential to shorten treatment duration?. Antimicrob Agents Chemother 50 (2006) 3543-3547
108. Ibrahim M., Andries K., Lounis N., Chauffour A., Truffot-Pernot C., Jarlier V., and Veziris N. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis?. Antimicrob Agents Chemother 51 (2007) 1011-1015
109. Ji B., Lefrancois S., Robert J., Chauffour A., Truffot C., and Jarlier V. In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans?. Antimicrob Agents Chemother 50 (2006) 1921-1926
110. Ji B., Chauffour A., Andries K., and Jarlier V. Bactericidal activities of R207910 and other newer antimicrobial agents against Mycobacterium leprae in mice?. Antimicrob Agents Chemother 50 (2006) 1558-1560
111. Conde M.B., and Villarino M.E. new agents for the treatment of tuberculosis on clinical study phases II/III?. Curr Resp Med Rev 3 (2007) 101-106
112. Barry C.E., Boshoff H., and Dowd C.S. Prospects for clinical introduction of nitroimidazole antibiotics for the treatment of tuberculosis?. Curr Pharm Des 10 (2004) 3239-3262
113. Nagarajan K., Shankar R.G., Rajappa S., Shenoy S.J., Costa-Pereira R., and Nitroimidazoles X. 2,3-Dihydro-6-nitro-imidazo [2,1-b] oxazoles with antitubercular activity?. Eur J Med Chem 24 (1989) 631-633
114. Ashtekar D.R., Costa-Perira R., Nagrajan K., Vishvanathan N., Bhatt A.D., and Rittel W. In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis?. Antimicrob Agents Chemother, 37 (1993) 183-186
115. Sasaki H., Haraguchi Y., Itotani M., Kuroda H., Hashizume H., Tomishige T., Kawasaki M., Matsumoto M., Komatsu M., and Tsubouchi H. Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydro-imidazo[2,1-b]oxazoles?. J Med Chem 49 (2006) 7854-7860
116. Matsumoto M., Hashizume H., Tomishige T., Kawasaki M., Tsubouchi H., Sasaki H., Shimokawa Y., and Komatsu M. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice?. PLoS Med 3 (2006) 2131-2144
117. th Sept 1997.
118. Stover C.K., Warrener P., VanDevanter D.R., Sherman D.R., Arain T.M., Langhorne M.H., Anderson S.W., Towell J.A., Yuan Y., McMurray D.N., Kreiswirth B.N., Barry C.E., and Baker W.R. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis?. Nature 405 (2000) 962-966
119. Manjunatha U.H., Boshoff H., Dowd C.S., Zhang L., Albert T.J., Norton J.E., Daniels L., Dick T., Pang S.S., and Barry C.E. Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis?. Proc Nat Acad Sci USA 103 (2006) 431-436
120. Bollo S., Nunez-Vergara L., and Squella J.A. Electrogenerated nitro radical anions: A comparative kinetic study using scanning electrochemical microscopy?. J Electrochem Soc 151 (2004) E322-E325
121. Nuermberger E., Rosenthal I., Tyagi S., Williams K.N., Almeida D., Peloquin C.A., Bishai W.R., and Grosset J.H. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis?. Antimicrob Agents Chemother 50 (2006) 2621-2625